Paris (France), 31 July 2008
Ipsen’s first half 2008 sales, outlook for the full year 2008 and R&D pipeline update
Acceleration of growth: +11.2% performance(1) sales growth, +7.4%reported(2). Strong specialist care sales growth: +13.3%. Growth outside the main Western European countries: +19.8%. Full year 2008 standalone sales objectives updated.
Acceleration of growth: +11.2% performance(1) sales growth, +7.4%reported(2). Strong specialist care sales growth: +13.3%. Growth outside the main Western European countries: +19.8%. Full year 2008 standalone sales objectives updated.
Paris (France), 23 July 2008
Ipsen continues the acquisition process of Tercica so as to establish its global presence in endocrinology
Subscription of additional shares of Tercica. Conversion of its notes. Exercise of its warrant. Ipsen now holds 42.6% of Tercica.
Subscription of additional shares of Tercica. Conversion of its notes. Exercise of its warrant. Ipsen now holds 42.6% of Tercica.
Paris (France), 17 July 2008
Ipsen completes purchase of all of OBI-1 assets from Octagen Corporation
Ipsen (Euronext: IPN) today announced that, following the announcement made on June 5, 2008 and the shareholder approval of Octagen Corporation, it has completed the purchase of all of the assets related to OBI-1. Ipsen paid accordingly to Octagen an upfront milestone of $10.5 million. Immediately following the effective transfer of all of the assets related to OBI-1, Ipsen will redeem its stake in Octagen.
Ipsen (Euronext: IPN) today announced that, following the announcement made on June 5, 2008 and the shareholder approval of Octagen Corporation, it has completed the purchase of all of the assets related to OBI-1. Ipsen paid accordingly to Octagen an upfront milestone of $10.5 million. Immediately following the effective transfer of all of the assets related to OBI-1, Ipsen will redeem its stake in Octagen.
